ZURICH (Reuters) - Drugmaker Polyphor is hiring new managers and shifting focus after a trial of its top antibiotic hopeful proved too dangerous to continue, the Swiss company said on Wednesday. Chief ...

Polyphor AG (VTX:POLN) shareholders will doubtless be very grateful to see the share price up 53% in the last month. But that isn't much consolation to those who have suffered through the declines of ...

Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, today announced closing of the ...

Allschwil, Switzerland, July 31, 2013 - Polyphor, a research-driven pharmaceutical company and leader in the discovery and development of macrocyclic drugs, today announced that Boehringer Ingelheim ...

ALLSCHWIL, SWITZERLAND / ACCESSWIRE / December 30, 2021 / Polyphor AG (SIX:POLN) and EnBiotix Inc. today announced the closing of the merger of the two companies and the change of name of the combined ...

ZURICH (Reuters) - Books for Swiss drugmaker Polyphor's (POLN.S) initial public offering are already covered less than half way through the subscription period, two people familiar with the ...

Co-primary endpoint of the study objective response rate (ORR) was not met The board of directors is undergoing a strategic assessment regarding the future of the company ALLSCHWIL, Switzerland, June ...

Polyphor AG (SIX: POLN) today provided an update regarding the recently announced evaluation of strategic options. This review has become necessary following the negative results of the FORTRESS study ...

Polyphor is closing its failed phase 3 breast cancer clinical trial and planning to lay off staff to lower its costs. The Swiss biotech said its “initial” restructuring will affect 29 positions and it ...

ALLSCHWIL, Switzerland, June 08, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing ...

Drugmaker Polyphor is hiring new managers and shifting focus after a trial of its top antibiotic hopeful proved too dangerous to continue, the Swiss company said on Wednesday. ZURICH, Sept 4 (Reuters) ...